Jpmorgan Chase & CO Elevation Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 61,334 shares of ELEV stock, worth $39,867. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,334
Previous 22,233
175.87%
Holding current value
$39,867
Previous $60,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ELEV
# of Institutions
68Shares Held
45.4MCall Options Held
700Put Options Held
27.6K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$3.9 Million0.19% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$3.09 Million0.24% of portfolio
-
Goldman Sachs Group Inc New York, NY3.99MShares$2.59 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.53MShares$2.29 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.07MShares$2 Million0.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $15.1M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...